9th Annual Pharmaceutical Strategic Outlook (PSO) Conference, April 11-13, 2012
This article was originally published in The Gold Sheet
You may also be interested in...
Company says it has learnt from gene therapy flop Glybera, and claims best-in-class status for viral vector.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.